JACOBIO-B (01167) announced that (1) Beijing Jacobio New Drug Research and Development Co., Ltd. (Beijing Jacobio) and Beijing Jacobio Ruikang Pharmaceutical Technology Co., Ltd. (Jacobio Ruikang) recently signed a capital increase agreement with an industrial partner; and (2) Beijing Jacobio, Jacobio Ruikang, Shanxi Haisong Management Consulting Partnership (Limited Partnership) (Haisong Capital), and the industrial partner recently entered into an equity transfer agreement. According to the capital increase and equity transfer agreements, Haisong Capital agrees to pay Beijing Jacobio RMB 125 million in cash as an initial payment and RMB 75 million as a second milestone payment to acquire 80% of Jacobio Ruikang's equity. Upon completion of the transaction, Jacobio Ruikang will be 10% owned by Beijing Jacobio, 80% owned by Haisong Capital, and 10% owned by the industrial partner. As of the date of this announcement, Beijing Jacobio holds 100% of the equity in Jacobio Ruikang, which is an indirectly controlled subsidiary of the company. Jacobio Ruikang's main business focuses on internally developing treatment drugs for cardiovascular diseases and holds intellectual property rights related to early cardiovascular research and development projects involved in this transaction. The announcement states that the company is committed to developing and providing new innovative oncology products and solutions to improve people's health. Jacobio Ruikang serves as a project company for an early cardiovascular research and development initiative within the group. This transaction aligns with the group’s strategic development focusing on key pipeline products in oncology targeting different critical cellular pathways (including KRAS, MYC, P53, and tumor immunity), optimizing capital allocation, fully securing the development of core oncology pipelines, achieving strategic focus, enhancing organizational efficiency, and retaining future project value through a risk-sharing model. The equity transfer consideration (after deducting various taxes and fees) is intended for the R&D, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects.